Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. - Wikidata - awgldk - TriplyDB

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

http://www.wikidata.org/entity/Q36254081

about

Immunobiology and immunotherapy in genitourinary malignancies A Perspective of Immunotherapy for Prostate Cancer Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy Immunotherapy for prostate cancer: recent developments and future challenges Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Potent anti-proliferative, pro-apoptotic activity of the Maytenus royleanus extract against prostate cancer cells: evidence in in-vitro and in-vivo models Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.Vaccines as monotherapy and in combination therapy for prostate cancer.Cancer immunotherapy: sipuleucel-T and beyond.Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Prostate cancer as a model for tumour immunotherapy.Impact of tumour volume on the potential efficacy of therapeutic vaccines.Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine Adding fuel to the fire: immunogenic intensification.Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer Update on prostate cancer vaccines The current and emerging role of immunotherapy in prostate cancer Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.Poxviral vectors for cancer immunotherapy Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Therapeutic cancer vaccines: the latest advancement in targeted therapy.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Immunotherapy for prostate cancer: biology and therapeutic approaches Emerging therapies in castrate-resistant prostate cancer.Immunotherapy and immune evasion in prostate cancer.State of the art in tumor antigen and biomarker discovery.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial Immunotherapy for prostate cancer: an emerging treatment modality.

P2860

Q26738668-DC4A29A4-85DF-47EE-A0CF-36E7D49B5ACE Q26741277-13E2D18A-E934-45F4-B325-3342C4830470 Q26827475-6EFF5085-7666-4BC2-BEB7-2C93CC9EF17E Q26851608-77010D23-3EAF-4469-8429-5B032ACC987A Q26852388-1C252E48-0E52-4512-AE0F-2D45FEDF222A Q27010542-AC174934-C3B6-4400-A12B-2A8F66221F26 Q27311628-444C8D30-B42C-435B-908F-A88208A62256 Q33621393-D951A424-8727-47A1-876E-C49DD1C39BF4 Q33642278-3C6B841F-663D-4D4C-9B29-1A3DC7F399AB Q33653836-D6859965-2F3F-4D21-BD60-3209273B3B56 Q33879368-C80A63D2-61A8-4A56-91B5-FB84E4A0E1AA Q34039068-9195B40E-D86B-4197-9838-11E580A969B2 Q34158070-BC549C78-F87A-4E8E-8220-483CA6DFA984 Q34444867-69B85FC4-6A4D-4053-8949-C954AABA4C88 Q34687216-E4759544-47B2-4FB4-99D0-92C6FC86F3E6 Q34856875-22E162FB-1B12-4639-9327-AD4D5B6DF68B Q35027034-4FC54558-5E54-4032-BABC-E5D90D40B7F7 Q35218994-90ECFF9E-26A7-46B7-BBFB-B215D1D42F5C Q35584269-DD34FE19-9CD1-4C92-9203-6F29ABB63BFA Q35757242-92579BE1-991E-43A9-857D-C368F9AB53DD Q35886393-7C07F386-D41D-4F42-B30C-607D4A87B6C5 Q35934137-0D56F9C6-4694-42DC-96F7-CCE67DFB8B47 Q36005476-FC6E6D83-7738-46FE-A048-DD34B558DEEC Q36169608-09EF564A-E8E0-471E-BCFF-DED3082697C1 Q36249922-86F4B4CF-A462-4E18-B0A5-C87393A4D6B5 Q36285594-49AE33E1-BCBC-459A-9BF8-233A59C68649 Q36293995-757F17B1-A00B-44E2-8DBD-1343B7201B52 Q36316871-BA61A2DC-A656-41B8-A6D5-83C7F8861BB3 Q36341084-F77D73DB-CA29-44C3-A296-010A8D08B30C Q36350388-D7A8BA6B-5DDE-4793-AE79-52C9131CFF84 Q36358303-8FBBE348-8057-4A7C-BD88-4D70D529EE25 Q36567448-A6FA0A0C-8684-4AA3-9894-A44A0A913245 Q36695629-CC46504E-C645-4619-845F-6D0618BCD6B2 Q36708792-E1943A0F-3271-4EC4-96C8-97F1F19CADF5 Q36910465-6306B8CB-DCCE-44B2-8EF3-1E9F0FDA9891 Q36929648-F4E0B23B-B1E4-4A9C-B91D-A9A31423BB34 Q37061769-0CAAAA43-8981-4756-BFA6-5E74F4AE5EA6 Q37132800-ACFDDCB8-683C-4CFF-AEBE-16AD22526B88 Q37684364-63FAA62D-6653-427E-9D3B-AB29BD976806 Q37691634-E8EF5294-27E4-45BE-81E6-8F0AA278AD72

P2860

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

http://www.wikidata.org/entity/Q36254081

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@ast

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@en

type

label

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@ast

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@en

prefLabel

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@ast

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@en

P1433

Q36254081-61088FA7-6A94-4B9E-AD59-3B8F665F07E5

P1476

Q36254081-2FD71EFB-6559-4059-A727-FF2CA92FF814

P2093

Q36254081-02F2B4EE-53E2-43A8-BAB1-A69A36C3BBF5

Q36254081-4628393F-A38B-4DF5-B1BF-7F57D1F619D8

Q36254081-4F7759B1-F79C-4D27-AD88-93456672519E

Q36254081-B80FAF65-CAF5-4116-8A17-826A954755E6

Q36254081-CE245607-AEC9-4A80-B97C-8D39EC30085D

P2860

Q36254081-00EB8D29-9029-4C9C-9106-D2AB6C6F8754

Q36254081-06BD05E8-A2F5-4B0C-8FEA-A78AE38E6359

Q36254081-15277C39-F616-4806-92F5-0FD64686D319

Q36254081-17675F86-E593-4FEB-9CC8-5363711D1A62

Q36254081-1E02C2BF-8620-4C0D-B19A-7E6736147FEC

Q36254081-21DEAEAD-3614-45BF-882C-73B5B3CA7F13

Q36254081-253DEBA7-2597-4A2E-A065-899409D802F8

Q36254081-25C79B2F-94C5-4919-8DFE-1EAF1F6521B2

Q36254081-25E6AB36-C116-4A79-A717-D7D66C4787CF

Q36254081-28DDC4CA-71AE-49B1-9693-8C0CD1F0C1EA

P304

Q36254081-3BBC199E-B4FA-465C-ADCF-D4304179C53C

P31

Q36254081-F23252FA-E65C-40AA-A561-E27D7CC15091

P356

Q36254081-395EE480-6990-4126-B109-80CB8484C1AD

P407

Q36254081-12DCCB20-4188-4696-86FC-C38C32DF1E48

P433

Q36254081-43B0DBF9-8172-4DB0-9A6B-AA5A9365E5E2

P478

Q36254081-BE198B10-BB57-47BA-8A3A-66349746DD79

P577

Q36254081-56A06DE3-A811-40F4-924C-98A43B6E9D6F

P5875

Q36254081-A9FB7C92-3F41-403C-8BA9-E775C3C98206

P698

Q36254081-CBF5AFA7-D05E-4149-8B83-4E85B93B6D93

P932

Q36254081-1148FFF4-9AB2-41E5-953F-0721B54A74E3

P356

13543780902997928

P1433

Expert Opinion on Investigational Drugs

P1476

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

@en

P2093

James L Gulley

http://www.w3.org/2001/XMLSchema#string

James W Hodge

http://www.w3.org/2001/XMLSchema#string

Mahsa Mohebtash

http://www.w3.org/2001/XMLSchema#string

Philip M Arlen

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Cancer statistics, 2008

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

P304

1001-1011

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543780902997928

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26313321

http://www.w3.org/2001/XMLSchema#string

P698

19548854

http://www.w3.org/2001/XMLSchema#string

P932

3449276

http://www.w3.org/2001/XMLSchema#string